Long-term administration of BAY 41-2272 prevents bladder dysfunction in nitric oxide-deficient rats

Neurourology and Urodynamics

Volumn 30, Issue 3, 2011, Pages 456-460

  Mónica, Fabíola Z ^a   Reges, Ricardo ^a   Cohen, David ^a   Silva, Fabio H ^a   De Nucci, Gilberto ^a   D'Ancona, Carlos A L ^a   Antunes, Edson ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

BAY 41 2272; Cystometry; Nitric oxide; Overactive bladder; Soluble guanylyl cyclase

Indexed keywords

4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; DIMETHYL SULFOXIDE; DRINKING WATER; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER DYSFUNCTION; BODY WEIGHT; CHRONIC DISEASE; CONTROLLED STUDY; CYSTOMETRY; MEAN ARTERIAL PRESSURE; MICTURITION; NONHUMAN; RAT;

ADMINISTRATION, ORAL; ANALYSIS OF VARIANCE; ANIMALS; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; GUANYLATE CYCLASE; MALE; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PRESSURE; PYRAZOLES; PYRIDINES; RATS; RATS, WISTAR; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TIME FACTORS; URINARY BLADDER; URINARY BLADDER, OVERACTIVE; URINATION; URODYNAMICS;

EID: 79952759390     PISSN: 07332467     EISSN: 15206777     Source Type: Journal    
DOI: 10.1002/nau.20992     Document Type: Article

References (28)

1. Andersson KE, Arner A. Urinary bladder contraction and relaxation: physiology and pathophysiology. Physiol Rev 2004;84:935-86. (Pubitemid 38823771)
2. Ho MH, Bhatia NN, Khorram O. Physiologic role of nitric oxide and nitric oxide synthase in female lower urinary tract. Curr Opin Obstet Gynecol 2004;16:423-9. (Pubitemid 41007546)
3. Fathian-Sabet B, Bloch W, Klotz T, et al. Localization of constitutive nitric oxide synthase isoforms and the nitric oxide target enzyme soluble guanylyl cyclase in the human bladder. J Urol 2001;165:1724-9. (Pubitemid 32410297)
4. Bennett BC, Kruse MN, Roppolo JR, et al. Neural control of urethral outlet activity in vivo: role of nitric oxide. J Urol 1995;153:2004-9.
5. Persson K, Igawa Y, Mattiasson A, et al. Effects of inhibition of the L-arginine/ nitric oxide pathway in the rat lower urinary tract in vivo and in vitro. Br J Pharmacol 1992;107:178-84.
6. Masuda H, Okuno T, Suzuki M, et al. Different distribution of nitric oxide synthase and soluble guanylyl cyclase activities in the detrusor and proximal urethra of the rabbit. J Urol 2002;168:2286-90.
7. Burnett AL, Calvin DC, Chamness SL, et al. Urinary bladder-urethral sphincter dysfunction in mice with targeted disruption of neuronal nitric oxide synthase models idiopathic voiding disorders in humans. Nat Med 1997;3:571-4. (Pubitemid 27198659)
8. Persson K, Pandita RK, Aszòdi A, et al. Functional characteristics of urinary tract smooth muscles in mice lacking cGMP protein kinase type I. Am J Physiol Regul Integr Comp Physiol 2000;279:R1112-20.
9. Mónica FZ, Bricola AA, Báu FR, et al. Long-term nitric oxide deficiency causes muscarinic supersensitivity and reduces beta(3)-adrenoceptor-mediated relaxation, causing rat detrusor overactivity. Br J Pharmacol 2008;153:1659-68.
10. Stasch JP, Becker EM, Alonso-Alija C, et al. NO-independent regulatory site on soluble guanylate cyclase. Nature 2001;410:212-5. (Pubitemid 32216593)
11. Baracat JS, Teixeira CE, Okuyama CE, et al. Relaxing effects induced by the soluble guanylyl cyclase stimulator BAY 41-2272 in human and rabbit corpus cavernosum. Eur J Pharmacol 2003;12:163-9. (Pubitemid 38373533)
12. Priviero FB, Baracat JS, Teixeira CE, et al. Mechanisms underlying relaxation of rabbit aorta by BAY 41-2272, a nitric oxide-independent soluble guanylate cyclase activator. Clin Exp Pharmacol Physiol 2005;32:728-34. (Pubitemid 41603152)
13. Teixeira CE, Priviero FB, Todd J, Jr., et al. Vasorelaxing effect of BAY 41-2272 in rat basilar artery: involvement of cGMP-dependent and independent mechanisms. Hypertension 2006;47:596-602. (Pubitemid 43843882)
14. Zanfolin M, Faro R, Araujo EG, et al. Protective effects of BAY 41-2272 (sGC stimulator) on hypertension, heart, and cardiomyocyte hypertrophy induced by chronic L-NAME treatment in rats. J Cardiovasc Pharmacol 2006; 47:391-5. (Pubitemid 44309692)
15. Schroder A, Hedlund P, Andersson KE. Carbon monoxide relaxes the female pig urethra as effectively as nitric oxide in the presence of YC-1. J Urol 2002;167:1892-6. (Pubitemid 34240777)
16. Toque HA, Antunes E, Teixeira CE, et al. Increased cyclic guanosine monophosphate synthesis and calcium entry blockade account for the relaxant activity of the nitric oxide-independent soluble guanylyl cyclase stimulator BAY 41-2272 in the rabbit penile urethra. Urology 2008;72:711-5.
17. Baú FR, Mónica FZ, Priviero FB, et al. Evaluation of the relaxant effect of the nitric oxide-independent soluble guanylyl cyclase stimulator BAY 41-2272 in isolated detrusor smooth muscle. Eur J Pharmacol 2010;637:171-7.
18. Ribeiro MO, Antunes E, Nucci G, et al. Chronic inhibition of nitric oxide synthesis: a new model of arterial hypertension. Hypertension 1992;20:298-303.
19. Persson K, lm P, Johansson K, et al. Nitric oxide synthase in pig lower urinary tract: immunohistochemistry, NADPH diaphorase, histochemistry and functional effects. Br J Pharmacol 1993;110:521-30. (Pubitemid 23279255)
20. Andersson KE, Persson K. Nitric oxide synthase and nitric oxide-mediated effects in lower urinary tract smooth muscles. World J Urol 1994;12:274-80.
21. Gamé X, Allard J, Escourrou G, et al. Estradiol increases urethral tone through the local inhibition of neuronal nitric oxide synthase expression. Am J Physiol Regul Integr Comp Physiol 2008;294:R851-7.
22. Soler R, Fullhase C, Lu B, et al. Bladder dysfunction in a new mutant mouse model with increased superoxide-lack of nitric oxide? J Urol 2010;183:780-5.
23. Mamas AM, Reynard JM, Brading AF. Nitric oxide and the lower urinary tract: current concepts, future prospects. Urology 2003;61:1079-85. (Pubitemid 36693973)
24. 2+ signalling in urethral interstitial cells of Cajal. J Physiol 2006;576:715-20.
25. Artim DE, Kullmann FA, Daugherty SL, et al. Activation of the nitric oxide-cGMP pathway reduces phasic contractions in neonatal rat bladder strips via protein kinase G. Am J Physiol Renal Physiol 2009;297:F333-40.
26. Reitz A, Knapp PA, Müntener M, et al. Oral nitric oxide donors: a new pharmacological approach to detrusor-sphincter dyssynergia in spinal cord injured patients? Eur Urol 2004;45:516-20.
27. Müntener M, Schurch B, Wefer B, et al. Systemic nitric oxide augmentation leads to a rapid decrease of the bladder outlet resistance in healthy men. Eur Urol 2006;50:112-7.
28. Osawa H, Chancellor MB, Jung SY, et al. Effect of intravesical nitric oxide therapy on cyclophosphamide-induced cystitis. J Urol 1999;162:2211-6.